Latest News and Press Releases

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

PORT CANAVERAL, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Structural Composites Inc. (SCI) has been awarded a competitively bid contract valued at more than $9 million by the U.S. Army Corps of...

Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM® System to address blood pressure instability after spinal cord injury (SCI)Blood...

NervGen Pharma today announced that the Company will ring the closing bell at the Nasdaq Stock Market on Thursday, January 22, 2026 in New York City

NervGen Pharma's common shares have been approved for listing on Nasdaq and will begin trading today, under the symbol "NGEN"

Belleville, Illinois, Sept. 29, 2025 (GLOBE NEWSWIRE) -- September is Spinal Cord Injury Awareness Month and Allsup Employment Services (AES), a Social Security-authorized Employment Network (EN)...

BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a...